Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Bullish +65

Becton, Dickinson And Company: BD Accelerates Advanced Tissue ...

AI-generated analysis

🏥 BD successfully completed enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for incisional hernia prevention.

📊 The study enrolled 477 patients across 32 sites in the United States and Europe.

🔬 This is the first large, randomized study assessing prophylactic reinforcement using a resorbable mesh for this indication.

⏳ Patients will be followed through a primary endpoint at 24 months with long-term follow-up planned for five years.

📝 Data from the study is expected to support a future submission to the U.S. Food and Drug Administration.

💡 The trial addresses a significant unmet need as no products are currently approved for incisional hernia prevention.

👤 Rian Seger, worldwide president of Surgery at BD, highlighted the commitment to extending advanced tissue regeneration into new patient care areas.

Bullish Signals
  • BD achieved a major milestone by completing enrollment in the PREVENT trial, validating its advanced tissue regeneration strategy and expansion efforts.
  • The study targets a significant unmet medical need for incisional hernia prevention, positioning Phasix™ Mesh as a potential first-in-class resorbable mesh solution.
  • Successful enrollment across 32 sites demonstrates strong clinical interest and operational execution capability in both the U.S. and Europe.
  • The trial aims to generate robust clinical evidence that could broaden the role of regenerative technologies, potentially creating new market opportunities.
Full Analysis
BD (Becton, Dickinson and Company) announced the successful completion of enrollment in the PREVENT clinical trial, a significant milestone for its advanced tissue regeneration strategy. The study evaluates Phasix™ Mesh for the prevention of incisional hernias following abdominal surgery, addressing a critical unmet need where no approved prophylactic products currently exist. The large-scale randomized study enrolled 477 patients across 32 sites in the United States and Europe. It represents the first major trial assessing prophylactic reinforcement using a resorbable mesh for this specific indication, aiming to generate robust clinical evidence for patients at high risk of post-surgical complications. Led by Rian Seger, worldwide president of Surgery at BD, the initiative seeks to extend the impact of regenerative technologies into new areas of patient care. Patients will be followed through a primary endpoint at 24 months, with longer-term safety evaluations planned for up to five years. Following the completion of primary assessments, data from the study is expected to support a planned submission to the U.S. Food and Drug Administration. This development aligns with BD's broader strategy of driving innovation across medical essentials and interventional solutions to optimize clinical operations and improve patient outcomes.